Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Adamson

Showing results (311-320 of 342) with videos related to

Pageof 35
Sort By:
Cancer Chemotherapy and Pharmacology|April 26, 2001
Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group studyE S Lowe, B J Kitchen, G Erdmann, et al.
Pediatric Blood & Cancer|December 19, 2013
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621)Elizabeth Fox, Yael P Mosse', Holly M Meany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.
The Journal of Molecular Diagnostics : JMD|April 6, 2020
Analytical Evaluation of the Abbott RealTime CT/NG Assay for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Rectal and Pharyngeal SwabsPaul C Adamson, Mark W Pandori, Sarah B Doernberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology GroupSuman Malempati, Brenda Weigel, Ashish M Ingle, et al.
Pediatric Blood & Cancer|May 7, 2015
Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology GroupKelly D Getz, Yimei Li, Todd A Alonzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology GroupKaci L Osenga, Jacquelyn A Hank, Mark R Albertini, et al.
Antimicrobial Agents and Chemotherapy|October 28, 2005
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescentsThomas J Walsh, Peter C Adamson, Nita L Seibel, et al.
Cancer|August 1, 1996
Phase II evaluation of topotecan for pediatric central nervous system tumorsS M Blaney, P C Phillips, R J Packer, et al.
Journal of the National Cancer Institute|October 21, 2004
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2Brigitte C Widemann, Frank M Balis, Aiman Shalabi, et al.
Pageof 35

Showing results (311-320 of 342) with videos related to

Sort By:
Pageof 35
Cancer Chemotherapy and Pharmacology|April 26, 2001
Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group studyE S Lowe, B J Kitchen, G Erdmann, et al.
Pediatric Blood & Cancer|December 19, 2013
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621)Elizabeth Fox, Yael P Mosse', Holly M Meany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.
The Journal of Molecular Diagnostics : JMD|April 6, 2020
Analytical Evaluation of the Abbott RealTime CT/NG Assay for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Rectal and Pharyngeal SwabsPaul C Adamson, Mark W Pandori, Sarah B Doernberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology GroupSuman Malempati, Brenda Weigel, Ashish M Ingle, et al.
Pediatric Blood & Cancer|May 7, 2015
Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology GroupKelly D Getz, Yimei Li, Todd A Alonzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology GroupKaci L Osenga, Jacquelyn A Hank, Mark R Albertini, et al.
Antimicrobial Agents and Chemotherapy|October 28, 2005
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescentsThomas J Walsh, Peter C Adamson, Nita L Seibel, et al.
Cancer|August 1, 1996
Phase II evaluation of topotecan for pediatric central nervous system tumorsS M Blaney, P C Phillips, R J Packer, et al.
Journal of the National Cancer Institute|October 21, 2004
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2Brigitte C Widemann, Frank M Balis, Aiman Shalabi, et al.
Pageof 35